Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer

This study has been terminated.
(The results of the dose escalation phase did not identify a well-tolerated dose that would permit further study in Phase 2.)
Information provided by (Responsible Party):
Kyowa Kirin Pharmaceutical Development, Inc. ( Kyowa Hakko Kirin Pharma, Inc. ) Identifier:
First received: September 8, 2010
Last updated: April 4, 2014
Last verified: April 2014
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: December 2012
  Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Dickson MA, P. LoRusso P, E. A. Sausville EA, Rao N, Kobayashi E, Kurman MR, Akinaga S, Schwartz GK. Open-label, sequential, ascending, multi-dose, phase I study of KW-2450 as monotherapy in subjects with previously treated advanced solid tumors. J Clin Oncol 29: 2011 (suppl; abstr 3078)